Document is current
Any future updates will be listed below
-
Authors
Hurrell, Alice https://orcid.org/0000-0002-5870-7629
Sparkes, Jenie https://orcid.org/0000-0002-9973-544X
Duhig, Kate https://orcid.org/0000-0001-9176-5671
Seed, Paul T. https://orcid.org/0000-0001-7904-7933
Myers, Jenny https://orcid.org/0000-0003-0913-2096
Battersby, Cheryl https://orcid.org/0000-0002-2898-553X
Clark, Katherine
Green, Marcus https://orcid.org/0000-0002-4561-8256
Hunter, Rachael M. https://orcid.org/0000-0002-7447-8934
Shennan, Andrew H. https://orcid.org/0000-0001-5273-3132
Chappell, Lucy C. https://orcid.org/0000-0001-6219-3379
Webster, Louise https://orcid.org/0000-0001-9050-4242
-
Funding
Funding for this research was provided by:
Tommy's (80)
- License Information
-
More Information
Article History
Received: 17 June 2022
Accepted: 7 August 2022
First Online: 2 September 2022
Declarations
:
: The trial will be conducted according to the principles of the Declaration of Helsinki (October 2008) and all applicable regulatory requirements. The conduct of this study will be in full compliance with Good Clinical Practice. Copies of the protocol, participant information leaflet, and informed consent form have been approved by Cambridge East Research Ethics Committee (19/EE/0322). The chief investigators or their delegate will submit and, where necessary, obtain approval from the relevant research ethics committee (REC) for any substantial amendments. All protocol modifications will be communicated promptly to sites once approved by the sponsor and the REC. Written informed consent will be obtained by the principal investigator or another member of the study team with delegated authority.
: Not applicable.
: AS has received funds from Perkin Elmer, paid to the university, to evaluate angiogenic markers. The other authors declare that they have no competing interests.
